2
|
Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, Cameron KO, Bhattacharya SK, Lapham K, McClure KF, Zhang Y, Jackson VM. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. Br J Pharmacol 2016; 173:1452-64. [PMID: 26784385 DOI: 10.1111/bph.13439] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 01/08/2016] [Accepted: 01/08/2016] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND AND PURPOSE Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose-dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small-molecule antagonist PF-05190457 and assess translational pharmacology ex vivo. EXPERIMENTAL APPROACH Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium-labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used as native tissues underlying food intake and insulin secretion respectively. KEY RESULTS PF-05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a human Kd of 3 nM requiring 4 h to achieve equilibrium. Potency of PF-05190457 was similar across different species. PF-05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration-dependent manner with similar potency but was threefold less potent as compared with the in vitro Ki in recombinant overexpressing cells. The effect of PF-05190457 on rodent islets was comparable with glibenclamide, but glucose-dependent and additive with the insulin secretagogue glucagon-like peptide-1. CONCLUSIONS AND IMPLICATIONS Together, these data provide the pharmacological in vitro and ex vivo characterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.
Collapse
Affiliation(s)
- J Kong
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - J Chuddy
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - I A Stock
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - P M Loria
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - S V Straub
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - C Vage
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - K O Cameron
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - S K Bhattacharya
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - K Lapham
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - K F McClure
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - Y Zhang
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| | - V M Jackson
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 01239, USA
| |
Collapse
|
4
|
McCoull W, Barton P, Brown AJH, Bowker SS, Cameron J, Clarke DS, Davies RDM, Dossetter AG, Ertan A, Fenwick M, Green C, Holmes JL, Martin N, Masters D, Moore JE, Newcombe NJ, Newton C, Pointon H, Robb GR, Sheldon C, Stokes S, Morgan D. Identification, Optimization, and Pharmacology of Acylurea GHS-R1a Inverse Agonists. J Med Chem 2014; 57:6128-40. [DOI: 10.1021/jm500610n] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- William McCoull
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Peter Barton
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | | | | | - Jennifer Cameron
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - David S. Clarke
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | | | | | - Anne Ertan
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Mark Fenwick
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Clive Green
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Jane L. Holmes
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Nathaniel Martin
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - David Masters
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Jane E. Moore
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | | | - Claire Newton
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Helen Pointon
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - Graeme R. Robb
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | | | - Stephen Stokes
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| | - David Morgan
- AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K
| |
Collapse
|
5
|
Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, Lapham K, Loria PM, Londregan AT, McClure KF, Orr STM, Patel J, Rose C, Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. ACS Med Chem Lett 2014; 5:474-9. [PMID: 24900864 DOI: 10.1021/ml400473x] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 02/18/2014] [Indexed: 01/15/2023] Open
Abstract
The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology led to the discovery of 16h. Compound 16h has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, 16h was advanced to human clinical trials.
Collapse
Affiliation(s)
- Samit K. Bhattacharya
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kim Andrews
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Ramsay Beveridge
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kimberly O. Cameron
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Chiliu Chen
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Matthew Dunn
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Dilinie Fernando
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Hua Gao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - V. Margaret Jackson
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Vishal Khot
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jimmy Kong
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Rachel E. Kosa
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kimberly Lapham
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Paula M. Loria
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Allyn T. Londregan
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kim F. McClure
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Suvi T. M. Orr
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jigna Patel
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Colin Rose
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - James Saenz
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Ingrid A. Stock
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Gregory Storer
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Maria VanVolkenburg
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Derek Vrieze
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Guoqiang Wang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jun Xiao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Yingxin Zhang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| |
Collapse
|